Literature DB >> 10728681

Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity.

T Nakashima1, M Miura, M Hara.   

Abstract

Bcl-2 is an integral, intracellular membrane protein that prevents cells from undergoing apoptosis in response to a variety of cell death signals. It negatively regulates the activation of Caspase-3, which functions as effector of mammalian cell death pathways. Overexpression of Bcl-2 inhibits the caspase activities and apoptosis. A microbial secondary metabolite, Tetrocarcin A (TC-A), was identified as an inhibitor of the anti-apoptotic function of Bcl-2. Apoptosis could be induced in cell lines that overexpressed Bcl-2 or Bcl-XL when the cells were treated with anti-Fas antibody, tumor necrosis factor alpha, staurosporine, or Bax, in addition to TC-A. TC-A showed selectivity against the pro-apoptotic Bcl-2 family members, in that cells overexpressing CrmA or dominant-negative FADD could not undergo apoptosis with TC-A treatment. In Bcl-2-overexpressing cell lines, TC-A inhibited mitochondrial functions regulated by Bcl-2, resulting in Fas-triggered mitochondrial transmembrane potential loss and cytochrome c release. Inhibition of the mitochondrial functions of Bcl-2 and, thereby, its anti-apoptotic effect could serve as useful pharmacological targets. Thus, TC-A should serve as an archetype for specific inhibitors of Bcl-2 functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728681

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  Targeting protein-protein interactions for cancer therapy.

Authors:  David C Fry; Lyubomir T Vassilev
Journal:  J Mol Med (Berl)       Date:  2005-11-11       Impact factor: 4.599

2.  Pharmacological manipulation of Bcl-2 family members to control cell death.

Authors:  Anthony Letai
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 3.  Emerging Bcl-2 inhibitors for the treatment of cancer.

Authors:  Asfar S Azmi; Zhiwei Wang; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Expert Opin Emerg Drugs       Date:  2010-09-03       Impact factor: 4.191

4.  Elucidation of the kijanimicin gene cluster: insights into the biosynthesis of spirotetronate antibiotics and nitrosugars.

Authors:  Hua Zhang; Jess A White-Phillip; Charles E Melançon; Hyung-jin Kwon; Wei-luen Yu; Hung-wen Liu
Journal:  J Am Chem Soc       Date:  2007-11-07       Impact factor: 15.419

5.  Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.

Authors:  Maria Berndtsson; Emma Hernlund; Maria C Shoshan; Stig Linder
Journal:  J Chem Biol       Date:  2009-03-31

Review 6.  Modulating splicing with small molecular inhibitors of the spliceosome.

Authors:  Kerstin A Effenberger; Veronica K Urabe; Melissa S Jurica
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-07-21       Impact factor: 9.957

7.  Synthetic Strategies Toward the Decalin Motif of Maklamicin and Related Spirotetronates.

Authors:  Michelle H Lacoske; Jing Xu; Noel Mansour; Chao Gao; Emmanuel A Theodorakis
Journal:  Org Chem Front       Date:  2015-04-01       Impact factor: 5.281

8.  Cloning and characterization of the tetrocarcin A gene cluster from Micromonospora chalcea NRRL 11289 reveals a highly conserved strategy for tetronate biosynthesis in spirotetronate antibiotics.

Authors:  Jie Fang; Yiping Zhang; Lijuan Huang; Xinying Jia; Qi Zhang; Xu Zhang; Gongli Tang; Wen Liu
Journal:  J Bacteriol       Date:  2008-06-27       Impact factor: 3.490

9.  A high-throughput splicing assay identifies new classes of inhibitors of human and yeast spliceosomes.

Authors:  Kerstin A Effenberger; Rhonda J Perriman; Walter M Bray; R Scott Lokey; Manuel Ares; Melissa S Jurica
Journal:  J Biomol Screen       Date:  2013-06-14

10.  Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.

Authors:  Walid Fayad; Mårten Fryknäs; Slavica Brnjic; Maria Hägg Olofsson; Rolf Larsson; Stig Linder
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.